Document: Presentations/fjnw0257.zip/fjnw0257.pdf
Category: Presentations
Processed: 2025-06-12T12:06:34.963775
Method: pymupdf+enhanced_ocr
Text Length: 25934 chars
==================================================

=== Page 1 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 1 Image 1 (OCR) ===
& Company EEE Wy

Corporate
performance
diagnostics

Discussion document
March 2020

@endo Y L

td J Wh
eg / f
OLE DEE T AL ALD PROPR E TARY. FAP SES J
Ang) asi Dns ake gs wltcabsres Dorin seca PR: Kosin Rss ran OC ae Sf bs ff)
ssbety pratt Ct ho

MCK-MAAG-2599303

=== Page 2 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 2 Image 1 (OCR) ===
Key issues

.

Opioid: Company is facing litigation related to opiaid overuse across many states in US Settled liabilities with

pice eit e emitter meee rm ei cre em imrecmre ia!

Oklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B — 4 0B

_ ets SASSER RSS AES ORNSSESS SSEGSESIIEDIEESUESISTEDSNCSOSENSS SEDSISERE SORES AEDST OSSISEN - ASSERSRE NE ENSGRSS SRE SASSI SESE ESESSESENEDS

Legal

Redacted

aime tetera terete eerie

Redacted

ime tetera terete eee:

ime tetera terete eee:

ee ee re ere ee et Ee EEE Reem meme meme:

vntovy

McKinsey & Company

MCK-MAAG-2599303.000001

=== Page 3 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 3 Image 1 (OCR) ===
Summary

* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

mine e tere ete erate erate ermine

etme tetetergieep rere teint ererererereree

5 growth is negative, cash flow did not cover liabilities, debt is below investment grade and

‘company is facing large potential litigation liabilities

ite teint eter ete re ere ere ete ee ete a en ee RR ee Rn RR Rn eR nn eR RI RR nn Rn RR eR RR RR ne A RI nn ee a ne ee nie nie eia emia ereieieiereiarermiete

Redacted

area eter eee eee eee eee ee ete ne eR en A ne RR ee Rn RR Re eR nn Re en nn ee ee nn ne nie nie einai e eee ainieieieeia eimieieieeiarermrererereier

McKinsey & Company

6 September 2020

MCK-MAAG-2599303.000002

=== Page 4 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 4 Image 1 (OCR) ===
Summary

* Endo is well performing operationally

Reet e tee eee eee tate tate imitates

ith higher margins than peers. However, due to issues related to

Redacted

opioid crisis,;

aise te tege ete re chet ere rime

_.; growth is negative, cash flow did not cover liabilities, debt is

ieee tere eter eter rere a ete ee ee a eR ee RR ee A ee RR RnR nn A Rn RR ne RR nn Rn eR Re RR ne A RI ne ee a ee a eee nie eie emia eieeieiereiarermieta,

below investment grade and company is facing large potential litigation liabilities

Redacted

ieee te eter teeter terete er erate re reterererereie

ieee ete eter ermine erate a ere ere ete ee a ere ete ene Re nln ne RR nS A nn A nn eA nn Rn en A ein a ein ete eine nie aia eine a eieiaiaimarereieieiermrmrerereiereres

McKinsey & Company

6 September 2020

MCK-MAAG-2599303.000003

=== Page 5 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 5 Image 1 (OCR) ===
Endo’s share price has declined ~90% in last 5 years mainly driven by

legal challenges and underperformance

Endo share price’

USD per share

SaaS =a S Sa a SS ae

pia = aaa = eae a eae aaa se amre

Sev eteiereveteierevererere:

120

Mar ‘16: Sued by FTC along

wth others ‘or illegally blocking

Redacted

Redacted

Redacted

oe

lower-cos: generic versions of

ded drugs Opana

eC

:

!

!

|

i. Redacted _j

eae,

eel aiwienecanienniagcete eiacoseeiscoss.

Leica ierersieievetcieieres =

:

Lesaive tee rcte tae rste reverse -

Stovatavateteiaiaievainbieveioiaeiot

80

mie te tetera res

ieee rere

Jun ‘17: Sued by Ohio Asorney General

ee ee

alongwith ‘our other pharma companies ‘or

‘heir alleged par: in dnung an opioid and

Prescnpion painkiller overdose epidemic

i

|

:

edacted

Viet

Redacted

Redacted !

cmon caiemsncncmiemeael

|

!

through aggressive marke'ing ‘ac‘ics

iste tetera eter reread

40 -

mie iin ahetetnaieieimnaisienmnany

Jun 17: FDA reques's.

pain medication, Opana

Endo ‘o rerrove rs opioid

ER, ‘ror the marke:

!

Lebacananas

ta iaiverStaievetctaiciercieicras4|

i

Jan 15

Jul 15

Jan 16

Jul 16

Jan 17

Jul 17

Jan 18

Jul 18

Jan 19

Jul 19

Jan 20

t

7A bet

77

s:

y

SAP Capla Tet rays s

McKinsey & Company

i]

MCK-MAAG-2599303.000004

=== Page 6 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 6 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEn ESSER SERS SSE SEnE ESSE SEnSSnESOSnSEnE SES SESERSSNE SESE SERS SESS SEnSSNSSESESERS DSSS SERSRESISEESSRESHSSE SIRENS SESnSSEESOSENSSRESSSSHSEESSRESSSESERISNSSHSESSnS SOSH SERSSSESESSESSSESSSSSERSSNSSHSSESSnSSSSESSnESNSSISSESSnESSSESERSNSSHSnSSESSSSESSSSNSSHSSISSSESHS=NSEnSSNSSOSSRSSRESESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSENSESSSNS DS SEnSSRESHSSNSESSSNE SE SnSSEE DESDE SEESSSSOSS

2599303.000005

=== Page 7 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 7 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEn ESSERE SSE SEnE SSDS RENE SESE SERS SESE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSnESOSASSRESHSSESERSSNSSESnSSEESNSENSSRESSSHSEESSRESSSNSEnSNSSHSESSnSSNSSESEnSSSESHSSESSSESSSSSERSSSSHSSESSRSSSSSNSSRESNSSISEESSnESHSSESERSSNSSHSnSSRSSNSSSSSSSNSSHSSASSRESHSSNSEnSSNSSOSSESSRSSESSNSTSSEESOSESSRESHSSSSTESSSESHSnSSES ONSEN SESSSNS SS SERSSNSSHSSNSISSSNE SE SnSSEESSSSESERSSNSSISS

2599303.000006

=== Page 8 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 8 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEn ESSENSE SERS nS S REEDS SERS SESS SERSSNE SESE SERS SESS SERSSNSSESESEES DSSS SERSNESHSEESSRESHSSESERSSNSSESSRSSRESNSSESSRSSSSHSSESSRESHSSESSRISNSSHSSESSES SOSH SERSSSSSOSSESSSESSSNSEnSSSSHSSESSnSSSSESSnESNSSISSESSRESSSESERSSESSHSnSSESSSSSSSnSSNSSHSENSSSESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSEESESSSNS SS SEnSSNSSHSSNSEnSSNE SE SEnSSES SESS SERSONSSOS

2599303.000007

=== Page 9 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 9 Image 1 (OCR) ===
Endo's revenue profile has remained flat and declined since 2016 driven

by both Branded and Gx segments

Endo's Revenue evolution by segment, 2014-19, USD bn, as reported

ee ae

etme e tetera eer rete rer ererereiety

@ Granded >harra i.

Pa

Redacted

i @ Genenc 2harra

i

i

:

Growth (2014-19),

Key takeaway

CAGR SE

pietetarerermeeratmermerer arm,

40

:

Redacted

8% p.a

-10% p.a.

eine tater e terete rete re rerere!

!

33

35

Branded Pharma portfolio

declining, driven by loss of

29

29

29

marketing exclusivity for

certain drugs and voluntary

withdrawal of OPANA® ER

se

from the market since

Fy201 7

(asa ates a ere eae e atereres 7

26

oo

23

03

Redacted

05

a3

02

ae

20°4

20°9

beeen eee eee erate ee =

Fete CES SOs OES CEs CES SOS OSSEDS CEOS SEE OES SESS OSE CES SUSE CES SU SSS OSE CES SES CSSOES CESSES SSESS CES SUSOSSOSSCES SUS OSS CES SUSE CES SUS OCES SUS OEOSU SOOO a

!

Redacted

!

soem

Sow

en cenicminiascemceiniciemsninscinmimianiaessncmsatmininiaraetaiaiminiarcsmsnininemsniacavmimiaiaessmes:

McKinsey & Company

)

MCK-MAAG-2599303.000008

=== Page 10 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 10 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena Sn SEn ESSERE SSE SEnE SSSR SNES SnSERE SESE SERSSnE SESE SERS SESS SERSSnSSESESEES SSSI SERSRESOSESSRESSSESERSSNSSESSnSSSESSSSSSRESSSHSERSSRESESSESERSNSSHSnSSES SSDS SEnSSSESESSnSSSESSSSESERSSSSHSSESSnSSSSESSRESNSSUSSASSRESSSESERSSESSHSESSRSSSSESSSSNSSHSSASSRESHSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSENSESSSNS SS SEnSSNSSHSSNSISSNE SE SnSSESSSSSESEESSSSIS

2599303.000009

=== Page 11 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 11 Image 1 (OCR) ===
Be ee ee ee

Redacted

nnn Ene rn SEnE ESSERE SSE SEnE SSS SESE RENE SESE SERE SES SE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSNESOSEESSRESHSSESEnSSNSSESnSSRESNSSESSRESSSHSSESSRESSSESERESNSSHSRSSSSSSSNSERSSSESOSSESSSESSSISERSSSSHSSESSnSSSSSSSSESNSSISSESSnE SSSI SERSSNSSHSESSRSSHSSESSnSSNSSHSERSSEE SSSA STnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSES ONSEN SESESNE SS SERSSRSSHSSNSESSNE SE SRSSROSSSSESEESOSSOS

AAG-2599303.000010

=== Page 12 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 12 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner EnE rn SEnE ESSERE SSE SEnE SSDS RENE SOS nSEnE SESE SEnSSnE SESE SERS SESS SERSSnS SES EESEES DSSS SERSRESOSEESSEESESSE SERENE SESSnSSRESNSSESSRESSSHSSESSRESSSESERSNSSHSESSRSSSSNSERESSS SOS SESSSESSSSSERSSSSHSSESSRSSSSSESSnSSNSSISSESSRESSSESERSSNSSHSnSSRSSOSSESSRSNESHSSRSSSESH SSN SInSSNSSOSSRSSRSSESSESTSSSNESESESERE SSDS STESSSESHSnSSES SSE SSSSSNS SS SERSSESSHSSNSINSNE SE SnSSROSSSESERSSSIS

AAG-2599303.000011

=== Page 13 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 13 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena Ene rn SEnE ESSERE SSE SEnE SSE SERENE SESE SEnE SES SE SERENE SESE SERS SESS SERSSNSSESESEES SSDS SERSRESHSNSSRESHSSESERSNSSHSnSSEESSENSSRESSSHSSESSRESSSESERSNSSHSESSESSISSNSERSSSSSOSSnSSSESSSSSERSSSSHSSESSRSSSSESSSSSNSSISEASSRE SSSI SERSSESSHSESSESSHSSESSSSNSSHSEISSEESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERESSSSSTSSSSESHSnSSES ONSEN SESSSNS SS SERSSNSSHSSSSISSNE SE SnSSROSSSSESEEDOSSISS

AAG-2599303.000012

=== Page 14 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 14 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nE rn SEnE ESSE SSE SEnE SSDS RENE SESE SERS SESS SERSSNE SESE SSNS SESS SERSSnSSESEASEEE SSDS SSRSNESISEESSRESESSESIRSSNSSESnSSRESSESSSRSSSSHSSESSRESSSSESERSNSSHSESSnSSHSSN SERENE SO SSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSISSESSRESHSSESERSSNSSHSnSSRSSSSESSSSNSSHSSASERESHSSNSInSSNSSOSSRSSRSSESSESTSSSNESESESERESSSSSSTSSSSESHSnSSES SSE SESISNE DS SEnSSRESHSENSISSNE SE SnSSROSSSSESEESSSOSS

AAG-2599303.000013

=== Page 15 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 15 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner ncn nS SERENE SSE SERE SSDS nSEnE SESE SERE SES SE SERENE SESE SSnSSOSSSSERSSNSSESESEES DSSS SERESNESHSEESSRESHSSESERSSNSSESnSSRESSSSSSRSSSSSHSSESSRESHSSESERSNSSHSnSSRSSHSSHSERSSSESOSSESSSESSSSSERSSSSHSSESSRSSSSSSSSESNSSISEASSRE SSSI SERSSNSSHSESSRESSSESSnESNSSHSSISSEESNSSNSEnSSNSSOSSRSSRSSESSESTSSNESESESERESSSSSSTESSSESHSnSSES SSSA SSSESNS DS SnSSRSSHSSNSEnSSNE SES ERSSRS DESDE SEESNSSIS

AAG-2599303.000014

=== Page 16 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 16 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner rn SEn ESSERE SSE SERE DOSES RENE SESE SEnE SESE SERENE SESE SSNS SESS SERSSnS SES EESEEE DSSS SSRSRESOSEESSRESHSSESERSSNSSESnSSEESSSNSSRSSSSHSSESSRESSSESERSNSSISESSRSSSSESERSSSESOSSESSSESSSSSERSSSSHSSESSRSSSSNSSnESNSSESSASSnESSSESERSSESSHSESSRSSSSESSSSNSSHSEISSRESHSSNSInSSNSSOSSnSSRSSESSNSTSSSnESOSESERESSSSSTESSSESHSnSSES SSSA SESESNS SS SEnSSNSSHSSNSESSNE SE SnSSRO DESDE SEESOSSOS

AAG-2599303.000015

=== Page 17 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 17 Image 1 (OCR) ===
re

Endo also has large potential litigation liabilities up to USD iresactes:

eine terete

Estimate

Liability

Opioid

"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement

implies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020

"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B

opioid charges paid over 10 years.” — Guggenheim, Nov 5", 2019

nS SSS SSE

Redacted

Linea te eee eee ee ete te eter eee a erate a ete ere ere a ete ere ete ee en ne ee nie nn nn en a nn ee ee a nin nie ete ein mia emia ein eie eam eiereieiereimrerereiees =

sor

ssp

vila og Areal:

rhe

vt

McKinsey & Company

7

MCK-MAAG-2599303.000016

=== Page 18 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 18 Image 1 (OCR) ===
Opioid portfolio currently consists of Percocet” that contributes

~14% of Branded Pharma and 4% of company revenue

"PERCOCET™. which is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain

The Company's pain products, including opioid products. are managed as mature brands and are not and have not been actively promoted for years. In

December 2016, the Company announced the elimination of its entire U.S. pain product field sales force

Generic Pharmaceuticals The Generic Pharmaceuticals segment includes a product portfolio of approximately 150 generic prescription product families

including solid oral extended-release. solid oral immediate-release. liquids, seni-solids, patches (which are medicated adhesive patches designed to deliver the

pharmaceutical through the skin), powders. ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions) and sprays and

includes products in the pain management. urology. central nervous system disorders, immunosuppression, oncology. women’s health and cardiovascular disease

markets, among others

- 10K 2019

Revenue in USO M

2019

Percocet

116

Branded Pharma

855

Percocet as % of Branded Pharma

14%

Endo total revenue

2.914

Percocet as % of Endo total revenue

4%

sor

wn tov)

18

McKinsey & Company

MCK-MAAG-2599303.000017

=== Page 19 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 19 Image 1 (OCR) ===
Summary

. Endo | is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

pice rete eet ere ele ete eter e te ar ebereiey

Redacted

Linen ee ee LE ee eee

igrowth is negative, cash flow did not cover liabilities, debt is below investment grade and

iste teint ete te eee erent eee ere re ee eR RR RR ee Rr RR nn A nn RR RR RR Re eR RR RR eR Rn Rn RR ne nn eee ni ee eee eimai ere ernie erie

company is facing large potential litigation liabilities

Redacted

iin tetera erate reer rere reer ererereierereiereieie

area tee erate eee eee ete ee ee ee ee Re ee Re eR RR RR ee A en A Re eR en eR ee en a ee ee eine eieeiaieinaeinieiaeineeieeiaemaeieeaeimeeieeerered

McKinsey & Company

19

6 September 2020

MCK-MAAG-2599303.000018

=== Page 20 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 20 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nE rn SEnE ESSE SSE SEnE SSDS RENE SESE SERS SESS SERSSNE SESE SSNS SESS SERSSnSSESEASEEE SSDS SSRSNESISEESSRESESSESIRSSNSSESnSSRESSESSSRSSSSHSSESSRESSSSESERSNSSHSESSnSSHSSN SERENE SO SSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSISSESSRESHSSESERSSNSSHSnSSRSSSSESSSSNSSHSSASERESHSSNSInSSNSSOSSRSSRSSESSESTSSSNESESESERESSSSSSTSSSSESHSnSSES SSE SESISNE DS SEnSSRESHSENSISSNE SE SnSSROSSSSESEESSSOSS

AAG-2599303.000019

=== Page 21 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 21 Image 1 (OCR) ===
Future cash flows from operations would be used up for litigation

and interest charges and debt repayments

Cumulative cash flow, FY2020-24, USD bn

Upside case

Downside case

potent ernie eter rete eter rete mieten ete rm eter mien tmr minim emir mie:

CFO betore interest i

ete eee ere eee ee ee ete a eee emp eee a eee eee ete eie eer ererermiere!

Redacted

Assumptions:

ews e sateen sree sese a ere rata saree se rsraa saree sererernsy

&changesinwe '

i

mie ietete terete teen

Lrigation charges

i

i

Redacted

etme teeter erate teeter terete ete eter eterelee ere erereterereierereetelereiererererereres|

[a

_

ie a sese se a tereeteta aerate ie serete esate a tees ateeiern

Opioid litigation liability estimated to range from

: Redacted !

USD 500M In Upside case to USD 4.0B in Downside

case (based on analyst reports), assumed to be

iesece eter reese res |

!

La faveietesereietesas, a

Tee eee ee cae saseteseietesniereseteiesmsnieiesnieinsy

repaid by FY2024

Redacted !

it

foe seie rete tere se, 7

it

it

Redacted

it

it

it

Redacted

it

it

it

it

it

1 Crete re ere e re ere rere ete erate aimee mre reres mr ererm mre res =

fp pina erie lei erie erate aise rns (ore rete sarees sopereioloreresosarer,

i

ota Simian ieinra es imine Simin re sre iere siete

Redacted

jetore sei eta ne sntat areata aieatate rn ietatere erate te eiatamieiataieieret=ss

McKinsey & Company

21

eine tee eter ete te erate a ete a ere ee ete ere ete a nie ete nin en A Rn RI nn RR eR Rn RR Rn RI eR A RI RIA nS A RI RR eR A RR Re RR nn en ne A nn en a nia nin mie a nie nie mieie mim nimi miereimie erm miermrmimimmienty

Redacted

ieee teeter rete re erate eee eee ere ete ere en a eR Re eR Re eR RI RR eR ne RI RR RR RR nn A Rn Re SR RR RR eR Rn RR ee A ne A ee A ne ne eee nie nin nee eimai mie eieeieremimierereierereinreree

MCK-MAAG-2599303.000020

=== Page 22 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 22 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner Ene rn SEnE ESSENSE SERS SnS SESE nEnE SESE SERE SES SESERSSnE SESE SERS SESS SERSSnSSESESEES SSDS SERSNESOSEESSRESESSESERSSNSSESnSSRESSSESSRSSNSSHSSESSRESHSSESERSNSSHSRSSESSISSESERESSESESSESSSESSSSISERSSNSSHSSESSRSSSSSESSRESNSSISEESSnESSSESERSSNSSHSESSRESOSSSSSSSNSSHSSISSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESERSSSSSSTESSSE SHS nSSES SSSA SESSSNS SS SRSSNESHSSNSISSNE SE SESSEESSSESESOSSIS

AAG-2599303.000021

=== Page 23 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 23 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena rn SEnE ESSERE SSE SEnE SSDS RENE SESE SERE SES SESERSSNE SESE SERS SESS SERSSNSSESESEES SSDS SSRESRESUSEASSRESHSSISERSSNSSUSSnSSEESSSSSSRSSSSHSSESSRESHSSESERISNSSHSnSSESSSSESERSSSE SS SESSSESSSESERSSNSSHSSnSSnESSSSSSSSSNSSHSSESSNESSSESERSSESSHSnSSRESSSSSSnSNSSESSISSRESNSSASInSSNSSUSSRSSRSSESSNSTSSSNESUSESSRESSSSSSTESSSESHSnSSES SSE SESSSNS DS SEnSSNESHSSNSESSSNE SE SnSSEE DESDE SEEEONSSISS

AAG-2599303.000022

=== Page 24 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 24 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nnn rn SEnE ESSER ENED S SERS nS SESE n ERE SOS SERS SESS SERENE SESE SERS SESS SEESSNSSESnSEES SSDS SERSSRESOSEESSRESESSESERSSNSSHSnSSRESSSSSSRESSSHSSESSRESSSESERSNSSISESSnS SOSH SEnSSSESESSESSSESSSISERSSSSHSSESSnESSSHSSSSSNSSISEESSRE SSSI SERSESSHSESSRSSSSSSSnSNSSHSSASSRESHSSNSEnSSNSSUSSRSSRSSESSESTSSSNESESESERESSSSSTESSSESHSnSSES ONSEN SSSISNS SS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEEESSSISS

2599303.000023

=== Page 25 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 25 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner ne rn SEnE ESSENSE SERS nS SEn SNE SOS SERS SES SESERSSNE SESE SERS SESE SERSSNSSESESEESSOSSESERESRESOSEESSRESSSESIRSSNSSHSnSSRESSSESSRESSSSHSERSSRESSSESSnSNSSHSSRSSRSSSSESEnSSSESESSESSSESSSSSEnSSNSSHSSESSRSSSSSSSSRESNSSUSEASSnESSSSE STRESS SH SESSRS SSDS SSSSNESHSSASSRESNSSNSInSSNS SUS SRSSRESESSNSTSSSNESESESSRESSSSSTESSSESHSnSSESSSEESSSISNS SS SERSSRSSHSSNSISSNE SE SnSSEESSSESERSONSSIS

AAG-2599303.000024

=== Page 26 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 26 Image 1 (OCR) ===
Analysts are concerned about Endo's ongoing opioid litigations,

significant levels of leverage and growth outlook

ope Oe aie ere ie ere eet erate ial miata mre reese aterm rere ieee cere rs

@ We are becoming more positive on ENDP from an opioid standpoint,

saw teaea aerate tater caravan!

SOM ia iai eine ta eimai are im retarel sinter crave vatitaie tary

;

Redacted

Redacted

ieee eter eee te erate a ere ere ete ee a ere ete ee a nie nie ere a a emia eee en nate amie mma a mnie mma mma minim mmm minim imimimimns

|

|

Gabelli, 14" Jan 2020

ore l a ere alae ie esare ese iateas ese 1are eles e.ere le ersten. e.clatare ie esa elerescreieseisrecetese a eielaersrease.eresereresey

pS ntareeeiatavene i atorere intone inten

©

Redacted

area etn: ewe vere

i

Vee ee ee ee ee ete eter ere ee eter niet et ete te mie er mieten ete ni mieten mieten miata tar mietm mein imi am tmrm mim rms

Redacted

+ Redacted |

ENDP’s high leverage

and ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock

RBC capital markets, 5" Nov 2019

aisle Siete ei ie te Sie aA ela eie tale Shia ae ieee Siete Siete ise lae ial eisieie;

a en ee ee

Redacted

So ee a ee ne

‘However, we continue to expect this dynamic to be

overshadowed by the ongoing opioid saga, which in our view remains a very significant risk given the company's branded

Rien Sinaia iar lace le Died ant Bij aib Serer e areata eae le mice ia, DladS ep aiuie le tia eta aA emetatatelaelaleisretaceleeiesnie

!

cotdvetere bes rerarareia ie ere terete

opioid portfolio/mkt share F’

i

aise teint eterna ete eter e rere ete ere ete a ere ere aie ere eie eee eee nie aie area eimai aieeieiemieiermimierermimreres

Redacted

lataiasavetntaieretala erate state tetete:

JP Morgan, 5 Nov 2019

1

McKinsey & Company

26

MCK-MAAG-2599303.000025

=== Page 27 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 27 Image 1 (OCR) ===
Analysts see upside driven by Endo's generic and sterile injectables

portfolio and CCH future potential

@ We are maintaining our Buy rating as we see significant potential upside if ENDP continues to execute, although we expect

investors to remain cautious in the near term given continued uncertainty regarding potential opioid liability and the recently

announced CEO change

SunTrust Robinson Humphrey, 11°? Nov 2019

(epee ia aia ieie ara aia mre ae areata araiase.eyacass-are

@ we expect investor focus to begin to increasingly dig into two issues (beyond opioids) i

ole eiataie lalate cialele a bicielatalele cleieie. ciitS lars aia etSiaiate Steele SSIS alah ciate aie. SiseS les iOtas

Redacted

|

Redacted

!

|

bee ee ee ee ee ete ete eee ete a ere ere ete a ere ere ete ere aie a ete eer e aie mie a ere a emia eee a ern a a a arm apermrmiarmrmiaimimrmimrmrmrmimrmrmrmrmemrmrmemed

RBC capital markets, 5'® Nov 2019

inte tater eter eee eter ete ete eee ee ete ee a ee ete ee Rn nein nn A ne nn nn Re ne a ne a nie eine na ein mini mie nimi mia ernie ere miami eieieie

@:

Redacted

|

ViavevcintavatStateietcin iste cieieletcveatetecietaterctelaierciaiaratSeisietcinietatcieiletatcvetelasietatercieiseiciaisreatdiaisietcieistatciaietesvetalecieiatectetevercs a

|

1

McKinsey & Company

27

MCK-MAAG-2599303.000026

=== Page 28 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 28 Image 1 (OCR) ===
Summary

Endo

well performi fe] operationally with higher margins than peers. However, due to issues related to opioid crisis,

a

Re

fed

Dee ete eee ere Sere ere eee eee

; growth is negative, cash flow did not cover liabilities, debt is below investment grade and

‘company is facing large potential litigation liabilities

etme teeter erate eee a ere ee ete ere en ee eR Re RR en RR RI RR nn A RI RR en eR Rn RR ne A nn eR ne A nn en eee nin ee eee einen eieiaieimimiermimieinieiay

Redacted

ite teint ere rete eter eet a ete ere ete a ete ere ee a nie nn RR en Rn Rn Re eR nn RR en A nn ne ne A nine ee nie ein ein a nie nineteen mia eimmieieeimierereiereres

McKinsey & Company

28

6 September 2020

MCK-MAAG-2599303.000027

=== Page 29 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 29 Image 1 (OCR) ===
Be ee ee ee

Redacted

nen rn SEnE ESSENSE SEnE SSS SE REEDED En SEnE SES SE SERENE SESE SERS SES EESERSSNSSESASEES DSSS SERSNESOSESSRESHSSESERSSNSSESnSSRESNSSSSSRESSSHSSESSRESSSESEnSNESHSESSES SSSA SERSSSESESSESSSESSSNSERSSSSHSSESSnSSSSSESSRESNSSHSSASSnESHSSESEnSSESSHSESSRESHSSESSnSNSSHSSnSSEESHSSNSInSSNSSOSSESSRESESSNSTSSNESESESERESSSSSSTESSSESHSnSSESSSSESSSSSNS SS SEnSSNSSHSSNSISSSNE SE SnSSEESSSSESESSNSSOSS

2599303.000028

=== Page 30 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 30 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nnn rn SEnE ESSER ENED S SERS nS SESE n ERE SOS SERS SESS SERENE SESE SERS SESS SEESSNSSESnSEES SSDS SERSSRESOSEESSRESESSESERSSNSSHSnSSRESSSSSSRESSSHSSESSRESSSESERSNSSISESSnS SOSH SEnSSSESESSESSSESSSISERSSSSHSSESSnESSSHSSSSSNSSISEESSRE SSSI SERSESSHSESSRSSSSSSSnSNSSHSSASSRESHSSNSEnSSNSSUSSRSSRSSESSESTSSSNESESESERESSSSSTESSSESHSnSSES ONSEN SSSISNS SS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEEESSSISS

2599303.000029

=== Page 31 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 31 Image 1 (OCR) ===
ERR ES

Redacted

Tn enn EnEDSnSEnE ES EESE RSENS SE SESEnE SE SSESEnENESESnSEnSSESSISESSSNSSESESSRSSHSSISSRSSNSSESEISSESSISSISSRSNSSHSIESSEESHSSNSSRSSNSSESSNSSEESHSENSSRSNSSHSSRSSRESHSSNSERISNSSHSInSSESSHSSNSERSNSSHSSNSSSESISSNSENSESSHSNSSESSSSNSSRESNSSHSNSSEESHSSESERSSESSHSESSESSHSSISSNSSNSSHSESERESHSENSERSSNSSHSSRESEOSESENSTSSSNESHSESERESNSSNSTEESNESHSTRSSESSHSENSESESNSDSSEnSSEOSHSSISISSSNE DE SRSSES DESDE SESSNSSO

2599303.000030

=== Page 32 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 32 Image 1 (OCR) ===
ERR ES

Redacted

Cnn nen Ener nSEnE SEES RSENS SE SnSEnESSSESERSnESESnSSRSSESSESERSSNSSESEESSRSSHSSSSTRESNSSESENSSESSISSISSRESNSSHSIRSSEESHSSNSORSSNSSHSSNSSEESHSENSSRSSNSSHSSRSSEESHSSNSERISNSSHSIRSSESSHSSNSERSSSSHSSNSSSOSHSSNSENSSNSSHSNSSEOSISSNSSRSSNSSHSNSSEESHSSESERSSNSSHSIESERSSHSSISSNSSNSSHSIESERESHSENSINSNSSHSnESEOSESSESTSSSNESHSESEROSNSSNSTSSSNESHSRSSEOSNSENSSNESNSDHSInSSEESHSSISISSSNS SE SERSSESSHSEESERSNSSISS

2599303.000031

=== Page 33 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/fjnw0257

=== Page 33 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner EnE rn SEnE ESSERE SSE SEnE SOS SESE RSE SOSnSEnE SES SE SERENE SESE SERS SESS SERSSNSSESASEES SSSI SERSRESHSASSRESESSESERSSNSSESnSSRESNSSESSRESSSHSERSSRESHSSESERISNSSHSnSSESSISSNSERSSSSSHSnSSSESSSSSERSSSSHSSESSRSSSSSNSSRSSNSSISEASSnE SSSI SERSSESSHSESSRSSSSESSSSNSSHSESSSSESHSSESInSSNSSUSSRSSRSSESSNSTSSSNESESESSRESHSSNSTESSSESHSnSSES SSE SSSSSNS SS SEnSSRESHSSNSESSNE SE SnSSEE DESDE SEESNSSISS

2599303.000032